Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPN

Rank in Stocks #4230
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Share Price
$29.72
Last synced: 2026-11-13
Market Cap
$3.51B
Change (1 day)
1.78%
Change (1 year)
-34.09%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Supernus Pharmaceuticals, Inc. (SUPN)

Category

Healthcare
Dividend history for Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (stock symbol: SUPN) made a total of 3 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $8.77
Dividend yield (TTM) : 27.36%
Dividend payments for Supernus Pharmaceuticals, Inc. (SUPN) from 2015 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
2026 (TTM) $8.13 1,611.58%
2016 $0.48 196.88%
2015 $0.16 0.00%
List of all dividend payments
Year Dividend Change
2026 (TTM) $8.13 8,457.89%
2016 $0.095 196.88%
2015 $0.032 0.00%
Dividend payments for similar companies or competitors

Questions about Supernus Pharmaceuticals, Inc.'s dividend per share

What is Supernus Pharmaceuticals, Inc.'s dividend per share?

Supernus Pharmaceuticals, Inc.'s dividend per share over the last twelve months is $8.13, as of Nov 2026.

What was Supernus Pharmaceuticals, Inc.'s dividend per share in 2016?

In 2016, Supernus Pharmaceuticals, Inc.'s dividend per share was $0.48, 196.88% more than in 2015 ($0.16).